Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas posted May 13 fiscal 2007 net revenue of ¥177.4 billion ($1.7 billion), a 32 percent increase over the ¥131.3 billion ($1.3 billion) posted the previous fiscal year. For the present fiscal year however, the Tokyo-based company, which focuses in urology, immunology and inflammatory, diabetes, CNS/pain, infectious diseases and cancer, forecasts a 10.4 percent drop in net revenue to ¥159 billion ($1.518 billion). In a May 14 earnings call with investors and analysts, company president and CEO Masafumi Nogimori noted sales of immunosuppressant Prograf (tacrolimus) grew in each region, with global sales of ¥203 billion. However, the drug's substance patent expired in April. "Based on this, U.S. sales will decline by 5.5 percent," Nogimori said
You may also be interested in...
Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
TOKYO - An Astellas Pharma senior executive said during a Feb. 2 earnings call the company is aiming to make its bid for CV Therapeutics a friendly proposal rather than a hostile takeover
Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline
TOKYO - An Astellas Pharma senior executive said during a Feb. 2 earnings call the company is aiming to make its bid for CV Therapeutics a friendly proposal rather than a hostile takeover
Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.
TOKYO - Astellas' Japanese domestic sales expanded 4.5 percent compared to last year, which analysts said were impressive because of the lowering of the National Health Insurance pricing across the board in April. The company attributed the increase to sales of long-acting angiotensin-II receptor antagonist Micardis (telmisartan), the hypnotic Myslee, and a few other products